Largest Study to Date Finds Pumps Result in Better Glucose Control Than Daily Injections
Caen, FR - Insulin pumps are significantly more effective at controlling blood glucose in people with type 2 diabetes who have failed to respond to the usual standard of care, multiple daily insulin injections, according to the largest international study to examine the safety and effectiveness of the pumps to treat type 2 diabetes, published in The Lancet.
Roughly a third of these patients in need of insulin therapy struggle to achieve the right level of blood sugar control with insulin injections many times a day. The growing obesity epidemic is adding to the problem by leading to greater insulin resistance.
Previous randomised trials comparing the efficacy of insulin pump therapy and multiple injections in people with type 2 diabetes have not provided consistent evidence, and the benefits of pump therapy continue to be debated.
The OpT2mise trial enrolled 495 adults (aged 30–75 years) with poorly controlled type 2 diabetes to a 2 month run-in period, where their insulin multiple daily injection treatment was optimised. After the run-in phase, the 331 participants whose HbA1c (glycated haemoglobin; an indicator of blood sugar control over the past 2 or 3 months) remained above the target range (≥ 8·0% and ≤12%) were randomly assigned to pump therapy or to continue with multiple injections.
Pumps outperformed multiple daily injections on several measures. The researchers found that people who used the pumps achieved a significantly greater reduction in average blood sugar levels than those who used multiple daily injections at 6 months (HbA1C difference of -0.7%). Twice as many patients also reached the target range of 8% or less in the pump-therapy group compared with the injection group (55% vs 28%). Patients using the pump also spent on average almost 3 hours less every day in hyperglycaemia (when blood sugar becomes too high). Continue>
Page | 1 2
Posted in: News Briefs | January 6, 2014
Preliminary Trial Data Shows Benefits But a Higher Risk of Non-Cardiovascular Death with Long-term Antiplatelet Therapy
Posted in: News Briefs | November 17, 2014
Posted in: News Briefs | May 13, 2016